Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose Interventions for Refractory Alcohol Use Disorder
NCT04562779Phase 1Completed
- Sponsor
- Denver Health
- Start
- Jan 2021
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of naltrexone and ketamine in alcohol use disorder (AUD) (3 arms), sponsored by Denver Health. Primary endpoints: Rate of 30-day Hospital Re-admission, Recruitment Rate at 12 months and 1 more. Started Jan 2021; status: completed.
02
Drugs
naltrexoneketamine
03
Conditions
alcohol use disorder (AUD)
Beyond the preview
Go deeper on NCT04562779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04562779.